Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsCreative Biolabs utilizes the proprietary High-Affi™ platform to supply researchers worldwide with antibodies specifically engineered to detect prenylated proteins. The platform's methodology covers both farnesylation and geranylgeranylation processes, ensuring these antibodies selectively identify prenyl-modified proteins while not recognizing free proteins.
Protein prenylation, alternatively described as isoprenoid modification or lipid anchoring, constitutes an evolutionarily conserved modification mechanism observed across cellular life forms. This permanent covalent alteration involves enzymatic conjugation of hydrophobic isoprenoid molecules to substrate proteins. Current classification recognizes two principal modification types mediated through distinct enzymatic pathways.
FTase and GGTase-I enzymes exhibit differential substrate specificities, facilitating 15-carbon farnesyl or 20-carbon geranylgeranyl group attachment to conserved cysteine residues within C-terminal CaaX sequences. Amino acid composition at the terminal position (X) determines enzymatic targeting: FTase substrates predominantly feature methionine, serine, glutamine, alanine, or cysteine residues, while GGTase-I preferentially modifies sequences terminating in leucine or glutamic acid. Additionally, GGTase-II mediates dual geranylgeranylation events occurring at characteristic CXC or CCXX motifs within Rab family proteins.
Fig.1 The prenylation process.1,3
Prenylation has drawn significant scientific attention owing to its multifaceted biological functions and disease associations. This biochemical modification increases protein hydrophobicity, enabling effective membrane attachment through interactions with plasma membranes or organelle surfaces. Notable substrates encompass Ras/Rho/Rab small GTPases, along with heterotrimeric G-proteins and lamin proteins maintaining nuclear structure. Beyond structural anchoring, the modification coordinates intracellular trafficking while mediating critical biomolecular interactions between proteins and membranes. Research confirms that defective prenylation mechanisms contribute to multiple pathologies, spanning oncological conditions, cardiovascular abnormalities, neurodegeneration, and rare genetic syndromes like retinitis pigmentosa and progeria.
Fig.2 CaaX prenylation and the eukaryotic cell cycle.2,3
Antibodies remain essential tools for examining protein prenylation across physiological and pathological conditions. Creative Biolabs possesses specialized capabilities in creating antibodies that specifically detect PTM. Our scientific team develops these reagents through rigorous optimization processes, providing both standardized off-the-shelf options and bespoke antibody solutions backed by performance warranties.
Our prenylation-targeting antibodies are available in polyclonal and monoclonal formats, developed using either modified peptide sequences or the isoprenoid modifications themselves as immunogens. These products are further classified according to their target specificity:
Pan-Prenylation Antibodies: Capable of detecting both farnesylated and geranylgeranylated proteins, these reagents focus on structural signatures shared across prenyl-modified targets rather than distinguishing modification types. Their binding profiles center on conserved features created during the prenylation process.
Farnesylation-Specific Antibodies: Engineered to interact exclusively with the 15-carbon farnesyl modification, these antibodies detect molecular configurations unique to proteins containing this specific prenyl group. Their selectivity arises from recognizing structural arrangements absent in other isoprenoid modifications.
Geranylgeranylation-Specific Antibodies: Specialized for identifying single or double 20-carbon geranylgeranyl attachments, this group discriminates against shorter-chain modifications through distinct molecular recognition patterns. The detection capacity extends to both mono- and di-geranylgeranylated protein forms.
Monospecific polyclonal antibodies targeting prenylated proteins are generated through immunization protocols using synthetic peptides containing prenylation sites coupled to carrier proteins. The harvested antiserum undergoes sequential purification steps involving depletion of antibodies recognizing unmodified peptides followed by enrichment for prenyl-specific binders. Compared to monoclonal approaches, this strategy yields antibodies with favorable binding capacities in shorter timelines while maintaining moderate specificity. The inherent polyclonal diversity enables simultaneous detection of multiple epitopes, improving assay sensitivity and experimental reproducibility across applications.
This in vitro platform employs bacteriophage libraries displaying antibody fragments to isolate monoclonal binders against prenylated antigens. Phage display can screen both libraries constructed by immunizing animals with corresponding targets and prefabricated antibody libraries derived from diverse sources. The process involves iterative exposure to immobilized targets, alternating with negative selection steps and phage amplification cycles. A key strength of this approach is its ability to access vast combinatorial diversity, enabling precise control over binding parameters. Researchers can systematically optimize antibody characteristics while identifying high-specificity clones against challenging isoprenoid modifications.
The classical hybridoma technique combines immunization with prenylated antigens, fusion of splenocytes with myeloma partners, and systematic screening for antigen-responsive clones. Validated hybridomas undergo clonal expansion to establish stable antibody-producing cell lines. Principal benefits derive from the generation of immortalized cell stocks producing antibodies with batch-to-batch consistency, native post-translational modifications, and superior performance in physiological environments compared to recombinant alternatives.
Custom Prenylated Peptide Antigens: We craft tailored peptide antigens that replicate native prenylation sites, incorporating precise farnesyl or geranylgeranyl groups. These synthetic mimics prioritize structural accuracy to selectively target prenyl-modified proteins over unmodified forms.
Prenylation-Specific Screening: Our screening platforms isolate antibodies binding exclusively to prenylated targets. The process integrates counter-selection steps to remove cross-reactive clones, ensuring early-stage specificity validation.
Specialized Immunization for Prenylated Antigens: Immunization protocols address Prenylated modifications' low immunogenicity. Optimized adjuvant regimens enhance immune recognition of hydrophobic epitopes, increasing yields of high-affinity, prenyl-specific antibodies.
Optimized Platforms for Prenylated Modifications: Phage display and hybridoma systems are modified to handle Prenylated-dependent epitopes. Adjustments include antigen stabilization methods and selection buffers preserving isoprenoid integrity during screening.
Specificity Characterization: Antibodies undergo multi-platform validation: ELISA comparing modified/unmodified targets, Western blot under varied conditions, and SPR analysis for binding kinetics.
Q: What are the key challenges in generating antibodies specific to prenylated proteins?
A: Producing antibodies that selectively target prenylated proteins faces technical hurdles stemming from the limited molecular footprint of isoprenoid groups and their structural overlap with unmodified counterparts. The hydrophobic properties of Prenylated modifications further complicate antigen-antibody interactions. Our antigen engineering capabilities, combined with multi-stage screening incorporating subtractive selection, address these challenges to isolate antibodies with precise recognition profiles.
Q: How do you ensure the antibodies you develop specifically recognize the prenylated form and not the unprenylated protein?
A: Ensuring specificity forms the cornerstone of our validation pipeline. We employ parallel testing across ELISA, Western blotting, and SPR platforms using both modified and native protein forms. This triangulated validation strategy systematically identifies and eliminates cross-reactive clones, ensuring final antibodies demonstrate negligible binding to non-prenylated targets.
Q: Do you offer any guarantees on the specificity and affinity of the antibodies generated?
A: While biological variability inherently exists, our process incorporates stringent quality assurance protocols. We guarantee full characterization of target specificity using gold-standard assays and work to meet mutually established affinity benchmarks, with iterative optimization available for critical parameters.
Q: What information do you need from us to start a prenylation-specific antibody discovery project?
A: Project initiation requires comprehensive target specifications: protein sequence data, confirmed modification sites (e.g., CaaX box details), and existing detection tools. These inputs guide antigen design and inform platform selection, ensuring alignment with your experimental requirements.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
